Proactive Investors - Run By Investors For Investors

BARD1 Life Sciences signs agreement to develop custom research assay

The company’s proprietary platform, BARD1, is based on novel tumour markers with potential diagnostic applications.
BARD1-Ovarian test
BARD1-Ovarian test is being developed for early detection of ovarian cancer

BARD1 Life Sciences Limited (ASX:BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development of a multiplex autoantibody test system.

The scope of work includes the transfer of the current BARD1 assay design to Thermo Fisher for optimisation of an autoantibody assay using Thermo Fisher’a ProcartaPlex® Technology for BARD1’s research use.

The first application of the ProcartaPlex® Technology is to the BARD1-Ovarian test that BARD1 plans to develop for detection of ovarian cancer.

The custom research assay development project will commence this month and is expected to take about nine months.

Evaluating the accuracy of the BARD1-Ovarian test

If the development project is successful, BARD1 and Thermo Fisher will then discuss the potential for Thermo Fisher to supply research autoantibody kits to BARD1 for its use in research studies.

BARD1 chief executive officer Dr Leearne Hinch said: “We are pleased to work with such an experienced partner.

“The development of a RUO BARD1 autoantibody assay for use on Luminex® instrumentation will be an important milestone for the company, enabling us to initiate clinical testing to evaluate the accuracy of the new multiplex BARD1-Ovarian test for early detection of ovarian cancer in early 2019.”

READ: BARD1 Life Sciences secures Israeli patent for unique lung cancer test

BARD1 was recently issued a patent in Israel for detecting BARD1 isoforms (proteins) in lung and colorectal cancer.

The company’s proprietary technology platform, BARD1, is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers.

BARD1’s patent portfolio comprises five patent families with multiple granted and pending patents across key markets including the US, Europe and Japan.

View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

Related Articles

lung x-ray
May 07 2019
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use